HighTower Advisors LLC Has $428,000 Stock Holdings in Collegium Pharmaceutical, Inc. (NASDAQ:COLL)

HighTower Advisors LLC reduced its stake in Collegium Pharmaceutical, Inc. (NASDAQ:COLL) by 2.9% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 14,956 shares of the specialty pharmaceutical company’s stock after selling 441 shares during the period. HighTower Advisors LLC’s holdings in Collegium Pharmaceutical were worth $428,000 at the end of the most recent quarter.

Other large investors also recently modified their holdings of the company. JPMorgan Chase & Co. lifted its holdings in shares of Collegium Pharmaceutical by 173.6% during the third quarter. JPMorgan Chase & Co. now owns 277,204 shares of the specialty pharmaceutical company’s stock worth $10,711,000 after buying an additional 175,892 shares in the last quarter. Barclays PLC boosted its holdings in Collegium Pharmaceutical by 152.2% in the 3rd quarter. Barclays PLC now owns 75,052 shares of the specialty pharmaceutical company’s stock valued at $2,899,000 after purchasing an additional 45,291 shares during the period. Sanctuary Advisors LLC grew its position in shares of Collegium Pharmaceutical by 10.7% during the 3rd quarter. Sanctuary Advisors LLC now owns 17,976 shares of the specialty pharmaceutical company’s stock worth $695,000 after purchasing an additional 1,731 shares in the last quarter. FMR LLC grew its position in shares of Collegium Pharmaceutical by 1,532.2% during the 3rd quarter. FMR LLC now owns 37,752 shares of the specialty pharmaceutical company’s stock worth $1,459,000 after purchasing an additional 35,439 shares in the last quarter. Finally, Janus Henderson Group PLC increased its holdings in shares of Collegium Pharmaceutical by 399.4% during the third quarter. Janus Henderson Group PLC now owns 69,485 shares of the specialty pharmaceutical company’s stock worth $2,686,000 after purchasing an additional 55,572 shares during the period.

Collegium Pharmaceutical Trading Up 0.5 %

Shares of COLL stock opened at $29.85 on Tuesday. Collegium Pharmaceutical, Inc. has a fifty-two week low of $27.28 and a fifty-two week high of $42.29. The stock’s fifty day moving average price is $30.29 and its two-hundred day moving average price is $32.35. The company has a debt-to-equity ratio of 3.43, a quick ratio of 0.88 and a current ratio of 0.97. The company has a market cap of $939.86 million, a PE ratio of 12.87 and a beta of 0.99.

Collegium Pharmaceutical (NASDAQ:COLL) last released its earnings results on Thursday, February 27th. The specialty pharmaceutical company reported $1.63 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.54 by $0.09. Collegium Pharmaceutical had a return on equity of 104.67% and a net margin of 14.78%. The firm had revenue of $181.95 million for the quarter, compared to analysts’ expectations of $179.68 million. Equities analysts predict that Collegium Pharmaceutical, Inc. will post 5.62 EPS for the current fiscal year.

Insider Activity at Collegium Pharmaceutical

In other news, EVP Shirley R. Kuhlmann sold 40,000 shares of the business’s stock in a transaction dated Tuesday, March 4th. The stock was sold at an average price of $28.08, for a total transaction of $1,123,200.00. Following the sale, the executive vice president now directly owns 154,204 shares in the company, valued at approximately $4,330,048.32. The trade was a 20.60 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CFO Colleen Tupper sold 1,949 shares of the firm’s stock in a transaction that occurred on Thursday, March 6th. The shares were sold at an average price of $30.00, for a total transaction of $58,470.00. Following the completion of the transaction, the chief financial officer now owns 177,195 shares of the company’s stock, valued at approximately $5,315,850. This trade represents a 1.09 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 109,193 shares of company stock valued at $3,243,594 in the last quarter. Insiders own 3.98% of the company’s stock.

Analyst Ratings Changes

A number of brokerages recently issued reports on COLL. Piper Sandler reduced their price target on Collegium Pharmaceutical from $37.00 to $36.00 and set a “neutral” rating on the stock in a research report on Tuesday, February 4th. Needham & Company LLC raised Collegium Pharmaceutical from a “hold” rating to a “buy” rating and set a $46.00 target price on the stock in a report on Friday, January 10th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $50.00 price target on shares of Collegium Pharmaceutical in a research note on Monday, March 24th. One analyst has rated the stock with a hold rating and five have given a buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $43.60.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.